WO2004020468A3 - Interferon beta-like molecules for treatment of cancer - Google Patents

Interferon beta-like molecules for treatment of cancer

Info

Publication number
WO2004020468A3
WO2004020468A3 PCT/DK2003/000554 DK0300554W WO2004020468A3 WO 2004020468 A3 WO2004020468 A3 WO 2004020468A3 DK 0300554 W DK0300554 W DK 0300554W WO 2004020468 A3 WO2004020468 A3 WO 2004020468A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
interferon
ifnb
half
life
mammal
Prior art date
Application number
PCT/DK2003/000554
Other languages
French (fr)
Other versions
WO2004020468A2 (en )
Inventor
Poul Soerensen
Original Assignee
Maxygen Aps
Poul Soerensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta

Abstract

The present invention relates to interferon β (IFNB) polypeptides with an increased half-life in the treatment of various cancers, in particular solid tumors. More particularly, the present invention is directed to a method of treating a mammal, in particular a human being, having a cancer, wherein said cancer has malignant cells carrying interferon type 1 deletions, by administering to said mammal a therapeutically effective dose of an IFNB polypeptide with increased functional in vivo half-life as compared to interferon β 1a. The present invention is also directed to a method of treating a mammal, in particular a human being, having cancer, comprising administering to said mammal a therapeutically effective dose of an interferon beta (IFNB) polypeptide with increased functional in vivo half-life as compared to interferon β 1a in combination with a chemotherapeutic agent. IFNB polypeptides with increased functional in vivo half-life are typically obtained through PEGylation of the IFNB polypeptide.
PCT/DK2003/000554 2002-08-28 2003-08-25 Interferon beta-like molecules for treatment of cancer WO2004020468A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US40718802 true 2002-08-28 2002-08-28
US60/407,188 2002-08-28

Publications (2)

Publication Number Publication Date
WO2004020468A2 true WO2004020468A2 (en) 2004-03-11
WO2004020468A3 true true WO2004020468A3 (en) 2004-06-10

Family

ID=31978437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000554 WO2004020468A3 (en) 2002-08-28 2003-08-25 Interferon beta-like molecules for treatment of cancer

Country Status (1)

Country Link
WO (1) WO2004020468A3 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
JP5207590B2 (en) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ,インコーポレイテッド Polymer conjugates of interferon -β with enhanced biological potency
CN101072797B (en) 2004-03-12 2012-05-09 瓦斯基因治疗公司 Antibody binding EPHB4, inhibiting angiogenesis and tumor growth
DK1730196T3 (en) 2004-03-12 2011-03-28 Vasgene Therapeutics Inc EphB4-binding antibodies to inhibit tumor growth and antiogenesis
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004080418A3 (en) 2003-03-12 2005-05-06 Parkash Gill Nucleic acid compounds for inhibiting angiogenesis and tumor growth
EP1799713B1 (en) * 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CA2813304A1 (en) * 2010-10-01 2012-04-05 Biogen Idec Ma Inc. Interferon-beta for use as monotherapy or in combination with other cancer therapies
WO2014157107A1 (en) * 2013-03-29 2014-10-02 株式会社糖鎖工学研究所 Polypeptide having sialylated sugar chains attached thereto

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271095A (en) * 1991-05-30 1993-10-19 Chugai Pharmaceut Co Ltd Anticancer agent
WO1998048018A1 (en) * 1997-04-23 1998-10-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Recombinant human beta interferon with enhanced solubility
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO1999055377A2 (en) * 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
JP2000109434A (en) * 1998-08-06 2000-04-18 Toray Ind Inc Inhibition of cell growth and cell growth inhibitor
WO2000023114A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Polymer conjugates of interferon beta- 1a and their uses
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2000068387A2 (en) * 1999-05-12 2000-11-16 Xencor, Inc. Nucleic acids and proteins with interferon-beta activity
WO2001015736A2 (en) * 1999-08-27 2001-03-08 Maxygen Aps Interferon-beta conjugates
WO2002036628A2 (en) * 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Kim Vilbour Andersen Variant growth hormone molecules conjugated with macromolecular compounds
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
WO2002074806A2 (en) * 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
WO2003002152A2 (en) * 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271095A (en) * 1991-05-30 1993-10-19 Chugai Pharmaceut Co Ltd Anticancer agent
WO1998048018A1 (en) * 1997-04-23 1998-10-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Recombinant human beta interferon with enhanced solubility
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO1999055377A2 (en) * 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
JP2000109434A (en) * 1998-08-06 2000-04-18 Toray Ind Inc Inhibition of cell growth and cell growth inhibitor
WO2000023114A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Polymer conjugates of interferon beta- 1a and their uses
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2000068387A2 (en) * 1999-05-12 2000-11-16 Xencor, Inc. Nucleic acids and proteins with interferon-beta activity
WO2001015736A2 (en) * 1999-08-27 2001-03-08 Maxygen Aps Interferon-beta conjugates
WO2002036628A2 (en) * 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Kim Vilbour Andersen Variant growth hormone molecules conjugated with macromolecular compounds
WO2002074806A2 (en) * 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
WO2003002152A2 (en) * 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCESCO RECCHIA ET AL: "Advanced Carcinoma of the Pancreas", AMERICAN JOURNAL OF CLINICAL ONCOLOGY, vol. 21, no. 3, 1998, pages 275 - 278, XP002263696 *
LAURA RUNKEL ET AL: "Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-Beta (IFN-Beta)", PHARMACEUTICAL RESEARCH, vol. 15, no. 4, 1998, pages 641 - 649, XP002271902 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 046 (C - 1157) 25 January 1994 (1994-01-25) *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 07 29 September 2000 (2000-09-29) *

Also Published As

Publication number Publication date Type
WO2004020468A2 (en) 2004-03-11 application

Similar Documents

Publication Publication Date Title
Richards et al. Mammalian zinc homeostasis: requirement for RNA and metallothionein synthesis
Kresina et al. Isolation and characterization of basement membrane collagen from human placental tissue. Evidence for the presence of two genetically distinct collagen chains
Hay et al. Mechanisms of bleomycin-induced lung damage
Bukowski et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study
SCHMITT et al. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance
Molineux Pegylation: engineering improved biopharmaceuticals for oncology
US5342940A (en) Polyethylene glycol derivatives, process for preparing the same
US20060171920A1 (en) Reversible pegylated drugs
Tsutsumi et al. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency
Na et al. Stability of PEGylated salmon calcitonin in nasal mucosa
Hellstrand et al. Histamine: a novel approach to cancer immunotherapy
Payne et al. Product development issues for PEGylated proteins
PRIES et al. Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma
Avila et al. A carcinoembryonic antigen‐directed immunotoxin built by linking a monoclonal antibody to a hemolytic toxin
Lutsenko et al. Targeting phthalocyanines to tumor cells using epidermal growth factor conjugates
WO2001024763A3 (en) Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
Deshmukh et al. A series of α-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity
MALKI et al. The heavy chains of human plasma inter-α-trypsin inhibitor: Their isolation, their identification by electrophoresis and partial sequencing. Differential reactivity with concanavalin A
JPS5995220A (en) Immunotherapeutic agent
Desai et al. Ubiquitin, SUMO‐1, and UCRP in Camptothecin Sensitivity and Resistance
WO2001032926A3 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
Hellstrand et al. Histamine in cancer immunotherapy
CN1687106A (en) Method of modifying protein alpha-amido by carbowax
CN1754889A (en) Pegylated interferon alpha-1b
Ito et al. Isolation and characterization of adenochrome, a unique iron (III)-binding peptide from Octopus vulgaris

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP